Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanezumab in Amyotrophic Lateral Sclerosis (ALS)
NCT01753076Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2012
- Primary completion
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of ozanezumab in amyotrophic lateral sclerosis (ALS), sponsored by GSK. Started Dec 2012; status: completed.
02
Drugs
ozanezumab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01753076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01753076.